Evidence map›Paper›PMID 41466536›Full record

ArticleFuture oncology (London, England)2026

Impact of radiation dose to immune cells on survival in patients with extensive-stage small cell lung cancer receiving consolidative thoracic radiotherapy after chemoimmunotherapy.

Changxing Feng, Kang Wang, Fuhao Xu, Li Li, Shuanghu Yuan

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Future oncology (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Changxing FengDepartment of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University, Jinan, Shandong, People's Republic of China.
Kang WangDepartment of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University, Jinan, Shandong, People's Republic of China.
Fuhao XuDepartment of Radiation Oncology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China.
Li LiDepartment of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University, Jinan, Shandong, People's Republic of China.
Shuanghu YuanDepartment of Radiation Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University, Jinan, Shandong, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundConsolidative thoracic radiotherapy (RT) following chemo-immunotherapy is increasingly used in extensive-stage small cell lung cancer (ES-SCLC). This study investigates the prognostic value of the estimated radiation dose to immune cells (EDRIC) and its determinants in these patients.

methodsThis retrospective study included 173 ES-SCLC patients between 2020 and 2023. EDRIC was calculated as a function of the number of fractions and the average doses to the lungs, heart, and remaining body. Kaplan-Meier and Cox regression analyses were performed to evaluate overall survival (OS) and progression-free survival (PFS).

resultsGTV, PTV, and N stage were positively correlated with EDRIC (r = 0.2577,

conclusionsEDRIC is an independent predictor of OS and PFS in ES-SCLC. These findings highlight the need to optimize radiation exposure to the immune system in cancer treatment.

Indexed as

Lung NeoplasmsSmall Cell Lung CarcinomaAdultAgedAged, 80 and overChemoradiotherapyFemaleHumansImmunotherapyKaplan-Meier EstimateMaleMiddle AgedNeoplasm StagingPrognosisRadiotherapy DosageRetrospective Studiesestimated dose of radiation to immune cellsExtensive-stage small cell lung cancerimmunologylymphocyte nadirsurvival

Identifiers

PMID41466536
PMCPMC12802987

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.